Met-Enkephalin: Physiology and What Research Reports

What Met-Enkephalin Is

Met-enkephalin is an endogenous opioid pentapeptide — a five-amino-acid chain with the sequence Tyr-Gly-Gly-Phe-Met. It belongs to the enkephalin family, whose other classic member is leu-enkephalin (Tyr-Gly-Gly-Phe-Leu), and it sits alongside beta-endorphin and the dynorphins in the broader group of opioid peptides the body makes itself. Because these peptides are frequently assayed together, clinical papers often report them as a panel: a 2007 study measured plasma met-enkephalin, beta-endorphin and leu-enkephalin levels in people with hepatic encephalopathy (PMID 17684846).

Where it is produced

Met-enkephalin is not transcribed directly. It is cleaved from a larger precursor protein, proenkephalin (gene PENK, historically "preproenkephalin"), which yields several copies of met-enkephalin and one of leu-enkephalin per molecule. For that reason researchers frequently measure the peptide and its precursor transcript in parallel rather than in isolation. A 2002 study examined met-enkephalin and preproenkephalin mRNA changes in the striatum of the nicotine abstinence mouse (PMID 12023068), and a 2024 poultry study measured circulating and tissue concentrations of met-enkephalin together with PENK expression (PMID 38603935).

Enkephalin-containing cells are distributed widely. Standard physiology texts place them in the striatum and basal ganglia, hypothalamus, brainstem and spinal cord dorsal horn, in the adrenal medulla, in the enteric nervous system, and in some immune cells. This anatomical spread is one reason the peptide is discussed in contexts as different as pain signalling, stress endocrinology and gastrointestinal motility.

What It Does in the Body

Met-enkephalin acts at opioid receptors, with a preference for the delta-opioid receptor and activity at the mu receptor as well. Like other opioid-receptor agonists it works through inhibitory G-protein signalling, reducing neuronal excitability and neurotransmitter release in the circuits where it is released. It is short-lived in extracellular fluid because peptidases such as aminopeptidase N and neprilysin cleave it quickly, which is central to how the peptide is studied — the molecule is a local, rapidly terminated signal rather than a long-circulating hormone.

Stress, the HPA axis and metabolism

Much of the recent animal literature treats met-enkephalin as a stress-responsive system measured next to glucocorticoids. Researchers examining restraint stress in chickens reported effects on circulating corticosterone and met enkephalin together with induced shifts in insulin secretion and carbohydrate metabolism (PMID 38473137). A companion 2024 study in young female chickens reported disparate effects of different stressors on met-enkephalin system parameters and on plasma concentrations of corticosterone, indicating that the peptide and the glucocorticoid response did not always move in the same direction (PMID 39123727).

Interaction with exogenous opioids

Because met-enkephalin shares receptors with opioid drugs, drug exposure is a recurring experimental probe. A 2024 research note reported that morphine influenced circulating and tissue concentrations of met-enkephalin and PENK expression, as well as plasma concentrations of corticosterone, in chickens (PMID 38603935). In the withdrawal direction, the study of nicotine abstinence in mice reported changes in striatal met-enkephalin and preproenkephalin mRNA (PMID 12023068), placing the enkephalin system inside the wider literature on reward and abstinence.

How Met-Enkephalin Is Measured or Studied

Four broad approaches appear in the verified literature summarised here:

• Immunoassay of plasma or tissue. Concentrations are quantified in blood or homogenised tissue, usually alongside related peptides or hormones, as in the hepatic encephalopathy panel of met-enkephalin, beta-endorphin and leu-enkephalin (PMID 17684846).
• Precursor gene expression. Preproenkephalin/PENK mRNA is measured to ask whether synthesis, not just peptide content, has shifted (PMID 12023068, PMID 38603935).
• Synthetic analogue chemistry. A 2006 paper described the synthesis, conformational and pharmacological study of glycosylated chimeric peptides combining met-enkephalin with FMRFa (PMID 16377439), an approach used to explore structure–activity relationships.
• Delivery systems. A 2016 study in Biomacromolecules developed smart polymeric nanocarriers of met-enkephalin (PMID 27409457), reflecting the general problem that small peptides are degraded rapidly and cross biological barriers poorly.

Snapshot of the cited work

Why the Term Matters to Readers

Met-enkephalin turns up in several different reading contexts. In neuroscience and pain literature it is one of the body's own opioid ligands, used to explain how endogenous signalling parallels opioid drug action. In stress physiology it appears as a measured variable next to corticosterone or cortisol, as in the chicken restraint-stress work that reported concurrent metabolic shifts (PMID 38473137). In clinical chemistry it appears as an analyte in patient populations (PMID 17684846). And in peptide chemistry it is a long-standing model compound for analogue design and delivery experiments (PMID 16377439, PMID 27409457). Encountering the same word across those settings does not mean the findings transfer between them.

Safety and Adverse Events: What Studies Report

The verified papers summarised on this page were observational human measurements, animal-model experiments and laboratory chemistry; none of them was framed as a human safety or tolerability trial of administered met-enkephalin, and no adverse-event profile can be drawn from them. The human paper cited here reported plasma concentrations in hepatic encephalopathy rather than outcomes after administration (PMID 17684846), while the animal work reported concentration and gene-expression changes following stressors or morphine exposure (PMID 39123727, PMID 38603935). This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or any substance you are considering.

Limitations of the Current Picture

1. Species spread. Several of the most recent findings came from chickens and mice, and researchers have not shown that the same directional changes occur in humans (PMID 38473137, PMID 12023068).
2. Measurement dependence. Plasma peptide concentrations reflect release, degradation and assay method at once, which complicates interpretation of panels such as the met-enkephalin, beta-endorphin and leu-enkephalin measurements reported in hepatic encephalopathy (PMID 17684846).
3. Divergent signals. The stressor study reported that different stressors did not affect met-enkephalin parameters and corticosterone uniformly (PMID 39123727), so a single "stress response" description oversimplifies the data.
4. Delivery remains a research problem. Nanocarrier and glycosylated-analogue work exists precisely because the native pentapeptide is not easily delivered intact (PMID 27409457, PMID 16377439).

References

• Plasma met-enkephalin, beta-endorphin and leu-enkephalin levels in human hepatic encephalopathy (Eastern Mediterranean Health Journal, 2007)
• Smart Polymeric Nanocarriers of Met-enkephalin (Biomacromolecules, 2016)
• Met-enkephalin and preproenkephalin mRNA changes in the striatum of the nicotine abstinence mouse (Neuroscience Letters, 2002)
• Disparate Effects of Stressors on Met-Enkephalin System Parameters and on Plasma Concentrations of Corticosterone in Young Female Chickens (Animals, 2024)
• Synthesis, conformational and pharmacological studies of glycosylated chimeric peptides of Met-enkephalin and FMRFa (Brain Research Bulletin, 2006)
• Effects of Restraint Stress on Circulating Corticosterone and Met Enkephalin in Chickens: Induction of Shifts in Insulin Secretion and Carbohydrate Metabolism (Animals, 2024)
• Research Note: Morphine influences circulating and tissue concentrations of met-enkephalin and proenkephalin (PENK) expression and plasma concentrations of corticosterone in chickens (Poultry Science, 2024)